Venue : Jordan International Exhibition Center (JIEC), Entry Gate No.: 3, Mecca Street, Amman JORDAN
The pharmaceutical industry is on the cusp of some significant transformations. This metamorphosis stems from a mix of technological advancements, changing demographics, and evolving market demands. As we look ahead, there are some prominent pharma industry trends ready to shape the future.
Through this article let us discuss some of these and how they might affect pharmaceutical manufacturing and the industry on the whole.
Reforms have always had a deep impact on the pharma industry. It was only a matter of time before the pandemic lessons started to be put into practice. Today, governments across the globe are rethinking the healthcare delivery system. Improving accessibility and reducing costs is the primary goal of most governments so that patient outcomes can be improved. Pharmaceutical manufacturers are headed for stringent access and pricing regulations as countries implement reforms to manage healthcare costs.
The US government has set up a list of 10 pharma products for price negotiation under the Inflation Reduction Act (IRA). The European Union, has a proposed legislation underway to shorten the exclusivity period for new drugs. It aims to bring it down from the present 10 years to eight if the drugs are not launched within two years in all of the 27 member states.
The AMNOG 2.0 Reforms are underway in Germany as well. These target the existing deficiencies in the country’s national pharmaceutical regulations so that drug prices can be controlled. Similarly, Italy is revamping its Italian Medicines Agency (AIFA). Asian countries like Japan and China are also taking steps to reduce drug prices through various governmental initiatives.
These global efforts suggest that pharmaceutical manufacturing and medicine manufacturing are likely to face major changes in revenue models as these reforms take root across the world.
There is also a significant shift towards increased investment in research to enhance the clinical value of products. This ties in line with the need for higher quality and safety standards with several countries pushing for universal healthcare coverage.
Pharma demand for cost-effective treatments is prompting pharmaceutical companies to streamline their manufacturing processes. This will boost the adoption of new technologies that can reduce production costs without compromising quality.
The COVID-19 pandemic highlighted the vulnerabilities in global supply chains, prompting a renewed focus on local manufacturing. Countries are increasingly prioritizing the development of local pharmaceutical manufacturing capabilities to ensure a stable supply of essential medicines.
Local manufacturing offers several advantages, including reduced dependency on international supply chains, quicker response times to local health crises, and the potential for lower production costs due to reduced shipping and import duties. Additionally, local manufacturing can be more adaptable to meet specific regional healthcare needs, which is particularly important for countries with unique epidemiological profiles.
Pharmaceutical companies are investing in local manufacturing facilities, leveraging advanced technologies such as modular manufacturing and continuous manufacturing processes. These innovations enable the production process to be flexible and efficient, with a steady supply of high-quality medicines.
With life expectancy increasing and birth rates decreasing, the global population is ageing. This major demographic shift is likely to shape the future of the pharmaceutical industry.
There is bound to be a change in the demand for medications that help manage chronic conditions. These include cardiovascular diseases, diabetes, and neurodegenerative disorders.
Pharmaceutical manufacturers are responding to this new requirement by developing new drugs suitable for older adults. These are focused more on treatments for age-related diseases, with lesser side effects. The medicines must also be easy to administer and personalise as per individual treatment plans and medication regimens.
As chronic diseases become more and more prevalent, the demand for long-term medication is also on the rise. Hence, pharma manufacturing processes need to adapt to large volumes of production with the same or better efficiency in order to meet the growing demand.
Sustainability is an important consideration in pharmaceutical manufacturing. Due to growing environmental concerns, more pharmaceutical giants are adopting sustainable practices in their operations.
With regulatory pressures tightening the noose, the focus is now centred on reducing the carbon footprint and implementing energy-efficient manufacturing processes. Hence, investments in renewable energy sources are increasing.
This shift towards sustainability also includes reducing waste generation and improving water management practices. Adopting green chemistry principles in medicine manufacturing helps with this. It allows companies to reduce the use of hazardous chemicals and develop eco-friendly formulations.
The development of sustainable packaging is another focal area besides manufacturing. As more pharmaceutical manufacturing companies aim to reduce plastic usage, the switch to recyclable or biodegradable materials is inevitable.
These efforts help protect the environment and allow companies to fulfil their corporate social responsibility. This aspect is fast gaining importance among consumers and investors alike.
The future of the pharma industry is being shaped by a combination of health system reforms, a focus on local manufacturing, demographic shifts, a shift to sustainability, and the inclusion of AI in manufacturing processes. These trends are driving significant changes in pharmaceutical manufacturing, from the way drugs are developed and produced to how they are delivered to patients. As the industry continues to evolve, pharmaceutical companies must adapt to these trends to remain competitive and meet the growing global demand for high-quality, affordable medications. Embracing these changes will not only improve patient outcomes but also contribute to a more sustainable and resilient healthcare system.